If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
5.40    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (3.774%)
Market Cap: £58.50m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Formo Secures a €35 million loan

21 Jan 2025 16:33

RNS Number : 1735U
Agronomics Limited
21 January 2025
 

 

Agronomics Limited

21 January 2025

 Agronomics Limited

("Agronomics" or the "Company")

Formo Secures a €35 million loan from the European Investment Bank

Agronomics (LSE: ANIC), a leading listed company in the field of cellular agriculture, is pleased to report that its portfolio company, Formo Bio GmbH, ("Formo"), has secured a €35 million loan from the European Investment Bank ("EIB").

The EIB loan is part of an initiative aimed at investing over €370 billion in new technologies by 2027 with the aim of supporting European companies developing innovative products in nascent, transformative markets.

Founded in Berlin in 2019, Formo specialises in utilising two technologies in its production of cellular agriculture products. The first is micro-fermentation, in which naturally occurring micro-organisms such as Formo's Koji mushrooms are used to produce proteins without modifying the micro-organism itself. Koji proteins are excellent for producing cheese without using animal products. Its work has also enabled Formo to develop bioidentical milk proteins, particularly caseins with good melting properties. Traditional fermentation is combined with the latest biotechnologies to produce caseins efficiently and on an industrial scale.

The €35 million loan follows the US$ 61 million in Series B funding that Formo secured in September 2024 - the third largest raise by an alternative protein startup last year - bringing Formo's total financing to over €135 million to date. The additional funds will be used to scale up manufacturing of its Koji protein cheeses and develop new products through its micro fermentation platform, in addition to securing regulatory clearance for its precision-fermented casein in the US and the EU.

Formo is already delivering key products to supermarket shelves across the continent. To date, it has launched its micro-fermentation product line, with several flavours of the cream cheese alternative Frischhain distributed to more than 2,000 METRO and REWE supermarkets in Germany and Austria since September 2024. Other cheese alternatives - from Greek feta to white and blue cheese, and an egg substitute for scrambled eggs and baked goods - are currently in the scaling process and preparing to be launched on the market.

Agronomics has invested €4.4 million in Formo, including the first investment in December 2019 when Agronomics co-led Formo's Seed round with M Ventures. The carrying value of Agronomics' position is £9.3 million accounting for approximately 5.8% of Agronomics' last stated Net Asset Value as at 30th September 2024. Agronomics holds an equity stake of 4.5% on a fully diluted basis.

Jim Mellon, Executive Chair of Agronomics, said: "Formo is leading the charge in the global transition towards animal-free proteins, with several popular products already serving a substantial area of the European market. The significant backing from the European Investment Bank is a testament to the quality of Formo's products, its commercial roadmap and its success to date. In addition, it will provide further financial resources to help Formo launch new products and continue to scale and expand its product offering across the rest of the continent - helping to bring ethical and sustainable agricultural products to millions more people."

About Formo

Formo is an innovative European fermentation startup that is redefining the future of cheese. Founded in 2019 with locations in Berlin and Frankfurt, Formo develops animal-free alternatives that combine taste and sustainability. Using state-of-the-art fermentation technology, Formo creates cheese alternatives that taste great and contribute positively to the environment. Learn more at https://formo.bio/.

About Agronomics

Agronomics is a leading London-listed company focussing on investment opportunities within the field of clean food. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

Anthony Hughes

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBBMFTMTJTBMA
Date   Source Headline
25th Jun 20267:00 amRNS-RPortfolio company Tropic acquires Rahan Meristem
4th Jun 20265:59 pmRNS-RAgronomics portfolio company HydGene Update
4th Jun 20265:58 pmRNS-RAgronomics portfolio company Bond Pet Foods Update
18th May 20267:00 amRNSNet Asset Value calculation as at 31 March 2026
12th May 20267:00 amRNSAgronomics leads US$5m investment in SuperMeat
7th May 20264:04 pmRNSMeatly completes £10.4 million Series A funding
15th Apr 20261:29 pmRNS-RClean Food Group Update
14th Apr 20267:00 amRNS-RTropic’s product receives regulatory approval
1st Apr 202612:50 pmRNS-RAll G secures FDA "no questions" letter
25th Mar 20263:45 pmRNS-RClean Food Group Update
19th Mar 202612:30 pmRNS-RTropic Biosciences Update
12th Mar 20265:31 pmRNSDirector's Dealing
4th Mar 20267:00 amRNSDirector’s Dealing
25th Feb 20265:04 pmRNSDirector’s Dealing
20th Feb 20265:15 pmRNSDirector’s Dealing
19th Feb 20262:10 pmRNSDirector’s Dealing
17th Feb 20267:00 amRNSHalf-year Financial Report
13th Feb 20264:31 pmRNSResult of AGM
9th Feb 20267:00 amRNSNet Asset Value calculation as at 31 December 2025
15th Jan 20267:00 amRNSAgronomics invests A$3m in All G & Issue of Equity
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
21st Nov 20258:00 amRNSAgronomics invests US$ 2 million in SuperMeat
13th Nov 20257:00 amRNSNet Asset Value as at 30 September 2025
10th Nov 20257:00 amRNS-REVERY raise US$ 55 million in fresh capital
21st Oct 20257:00 amRNS-RGeltor, Inc Update
30th Sep 20257:00 amRNS-RClean Food Group Update
23rd Sep 20257:00 amRNS-ROnego Bio Update
12th Sep 20258:00 amRNS-RClean Food Group Update
22nd Aug 20258:19 amRNS-RMeatable acquires Meat Technology platform
24th Jul 20257:00 amRNS-RSolar Foods Update
18th Jul 202511:00 amRNSNet Asset Value calculation as at 30 June 2025
11th Jun 20257:00 amRNS-RAgronomics Q2 2025 Newsletter
28th May 20252:55 pmRNS-RMeatly reduces bioreactor and medium costs
12th May 20257:00 amRNSNet Asset Value calculation as at 31 March 2025
8th May 20257:00 amRNS-RLiberation Labs Announce Manufacturing Partnership
6th May 20257:00 amRNS-RMeatable and TruMeat Forge Alliance
30th Apr 20257:00 amRNS-RBlueNalu Expands Partnership with Nomad Foods
15th Apr 20259:00 amRNS-RLiberation Labs secures strategic partnership
18th Mar 20257:00 amRNSExercise of Shellbay options
14th Mar 20258:15 amRNSUnaudited Interim Results
4th Mar 20258:00 amRNS-RSolar Foods Secures €10 million Grant
7th Feb 20253:33 pmRNSResult of AGM
7th Feb 20257:00 amRNS-RMeatly launches first cultivated meat dog treat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.